CN101912441A - Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof - Google Patents
Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof Download PDFInfo
- Publication number
- CN101912441A CN101912441A CN 201010256454 CN201010256454A CN101912441A CN 101912441 A CN101912441 A CN 101912441A CN 201010256454 CN201010256454 CN 201010256454 CN 201010256454 A CN201010256454 A CN 201010256454A CN 101912441 A CN101912441 A CN 101912441A
- Authority
- CN
- China
- Prior art keywords
- preparation
- salviae miltiorrhizae
- radix salviae
- component composition
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng effective parts and a preparation method thereof and also relates to application of a drug prepared from the effective part composite in preventing and curing cardiovascular and cerebrovascular diseases, senile dementia, cerebral infarction, cerebral ischemia and other various diseases caused by cerebral ischemia, belonging to the technical field of traditional Chinese medicine. The composite comprises the following drug components in parts by weight: 10-99 parts of total salvianolic acid, 0-50 parts of tanshinone, 10-99 parts of panax notoginseng saponins, 0-50 parts of dalbergia wood general flavone and 0-20 parts of dalbergia wood oil total terpenoid. The effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng, which is disclosed by the invention, has better action of resisting myocardial ischemia, has certain action of resisting thrombopoiesis and anticoagulation, improves peroxide of cardiac muscular tissues during myocardial ischemia resistance, improves medical hemorheology and performs the efficacy of paths which affect clotting functions.
Description
Technical field
The present invention relates to contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition and preparation method thereof; And the medicine of this active component composition preparation uses in control cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and other various diseases medicines of being caused by cerebral ischemia thereof, belongs to technical field of Chinese medicines.
Background technology
The cardiovascular diseases is commonly encountered diseases and the frequently-occurring disease that middle-aged and elderly people is easily suffered from, and human beings'health in serious harm.Wherein the example that coronary heart disease is fallen ill of China is annual above 1,000,000 people, and Incidence of CHD presents the trend that rises year by year.Show that according to epidemiological study population of China cardiovascular diseases's mortality rate accounts for 40% in the total death of population.Aggravation along with China's aged tendency of population trend, geriatric cardiovascular disease becomes increasingly conspicuous, and become the lethal first cause of disabling, day by day seriously threatening human beings'health and life, therefore to cardiovascular diseases's especially coronary heart disease treatment study on prevention, be social and one of the focus of medical circle concern and difficult point, have good DEVELOPMENT PROSPECT.
The preparation for the treatment of similar disease does not in the market all solve problems such as dose is big, bioavailability is low, quality standard controllability is bad, effective ingredient can not effectively utilize, its technology all is traditional technology basically, there is not any new technology transfer, can't occupy enough market, more be difficult to open the international market.Therefore, be necessary that further investigation contains Radix Salviae Miltiorrhizae, Sanchi effective-component and exploitation active component composition preparation, thereby for a kind of better efficacy, more convenient, quality controllable, safe and reliable effective ingredient in Chinese compound preparation are provided clinically.
Summary of the invention
The objective of the invention is to adopt modern advanced extraction, purification by macroporous resin isolation technics, preparation technique and Quality Control Technology, prepare the Chinese medicine preparation of the treatment cardiovascular disease that a kind of cost is low, drug effect is high, have no side effect---contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition preparation and preparation method thereof.The present invention openly contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition has function of resisting myocardial ischemia preferably, and has certain antithrombotic to form and blood coagulation resisting function; It can by reduce myocardial oxygen consumption, improve the blood supply of cardiac muscle oxygen supply, improve cardiac muscle to the toleration of hypoxic-ischemic, when resisting myocardial ischemia cardiac muscular tissue peroxidating, improve hemorheological effect and to the effect of approach such as the influence performance of coagulation function.
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
Radix Salviae Miltiorrhizae total phenolic acids 10-99 part TANSHINONES 0-50 part
Radix Notoginseng total arasaponins 10-99 part Lignum Dalbergiae Odoriferae total flavones 0-50 part
The total terpene 0-20 of Lignum Dalbergiae Odoriferae oil part.
A kind of preparation method that contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition, its preparation method may further comprise the steps:
A, weight portion content 50% above preparing salvianolic acids: red rooted salvia water extract is refining through macroporous adsorbent resin, and first water eluting discards water lotion, and the reuse ethanol elution is collected eluent, and concentrating under reduced pressure is drying to obtain.
The preparation method of B, weight portion content 50% above TANSHINONES: red rooted salvia water extract, concentrating under reduced pressure, aqueous precipitation, drying both got.
The preparation method of C, weight portion content 50% above Radix Notoginseng total arasaponins: macroporous adsorptive resins on the pseudo-ginseng water extract, first water eluting discards water lotion, and the reuse ethanol elution is collected eluent, reclaims ethanol, and concentrating under reduced pressure is drying to obtain.
The preparation method of D, the total terpene of weight portion content 50% above Lignum Dalbergiae Odoriferae oil volatility: the Lignum Dalbergiae Odoriferae medical material cuts off, and soaks, and vapor distillation is collected fraction, uses anhydrous sodium sulfate drying, promptly.
The preparation method of E, weight portion content 50% above Lignum Dalbergiae Odoriferae total flavones: Lignum Dalbergiae Odoriferae medical material alcohol extract, concentrate, add the water standardize solution, last macroporous adsorptive resins, washing, ethanol elution is collected alcohol eluen, and concentrate drying both got.
F, the said extracted thing is mixed, packing promptly.
The dosage form of this active component composition preparation can be tablet, capsule, oral liquid, injection, injectable powder, transdermal formulation, mucosa absorption preparation.
A kind of purposes that contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition is to be used to other various diseases of preventing and treating cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and being caused by cerebral ischemia.
In view of pharmaceutical dosage form and the needs that produce to use, can be on the basis of above-mentioned prescription reasonable pharmaceutic adjuvants such as absorb fillers, excipient, pH value regulator, correctives, cosolvent, antioxidant, to satisfy drug manufacture and use.
Below be to be introduced to inventing selected Chinese medicine extract:
Radix Salviae Miltiorrhizae total phenolic acids has remarkable coronary artery dilator, coronary blood flow increasing, reduce myocardial oxygen consumption, decreased heart rate increases myocardial contraction, reduces neutral fat, prolong the mice hypoxia endurance time, alleviate the myocardial damage that anoxia causes, promote cardiac muscle regeneration, suppress the ADP induced platelet aggregation, suppress the synthetic of platelet T XA2 and discharge vaso-excitor material and promote the fibrin degradation effect; TANSHINONES has inhibition vascular smooth muscle cell proliferation, suppress vascellum endometrial hyperplasia, improve coronary artery, dwindle myocardial infarction area, alleviate myocardial ischemia reperfusion injury, prevent myocardial hypertrophy, anti-arrhythmia alleviates the cerebral hypoxia ischemia damage, the control reperfusion injury, antithrombotic forms, antiplatelet aggregation, the system heart and brain microsome Na
+, K
+-ATP enzyme Na
+, K
+Effects such as-ATP enzyme and positive inotropic action and anti-inflammatory, antibacterial antitumor;
Radix Notoginseng total arasaponins has the body of raising to anoxybiotic tolerance, and anticoagulant improves effects such as myocardial ischemia, anti-arrhythmia, blood fat reducing, blood pressure lowering, antithrombotic, analgesia, calmness;
Volatile oil of Lignum Dalbergiae Odoriferae has the platelet of raising cAMP content, has the thrombotic effect of inhibition, can resist myocardial ischemia and increase coronary flow, and wherein volatility terpenoid such as nerolidol, oxidation nerolidol is the main active of Lignum Dalbergiae Odoriferae oil; The Lignum Dalbergiae Odoriferae total flavones has effects such as antioxidation, antiinflammatory, analgesia, anticancer and lax blood vessel.
The present invention openly contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition has function of resisting myocardial ischemia preferably, and has certain antithrombotic to form and blood coagulation resisting function; It can by reduce myocardial oxygen consumption, improve the blood supply of cardiac muscle oxygen supply, improve cardiac muscle to the toleration of hypoxic-ischemic, when resisting myocardial ischemia cardiac muscular tissue peroxidating, improve hemorheological effect and to the effect of approach such as the influence performance of coagulation function.
The specific embodiment
Embodiment 1
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
10 parts of 20 parts of Radix Notoginseng total arasaponinss of 10 parts of TANSHINONES of Radix Salviae Miltiorrhizae total phenolic acids
10 parts of the total terpenes of 50 parts of Lignum Dalbergiae Odoriferae oils of Lignum Dalbergiae Odoriferae total flavones.
A kind of preparation method that contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition, its preparation method may further comprise the steps:
A, weight portion content 50% above preparing salvianolic acids: red rooted salvia water extract is refining through macroporous adsorbent resin, and first water eluting discards water lotion, and the reuse ethanol elution is collected eluent, and concentrating under reduced pressure is drying to obtain.
The preparation method of B, weight portion content 50% above TANSHINONES: red rooted salvia water extract, concentrating under reduced pressure, aqueous precipitation, drying both got.
The preparation method of C, weight portion content 50% above Radix Notoginseng total arasaponins: macroporous adsorptive resins on the pseudo-ginseng water extract, first water eluting discards water lotion, and the reuse ethanol elution is collected eluent, reclaims ethanol, and concentrating under reduced pressure is drying to obtain.
The preparation method of D, the total terpene of weight portion content 50% above Lignum Dalbergiae Odoriferae oil volatility: the Lignum Dalbergiae Odoriferae medical material cuts off, and soaks, and vapor distillation is collected fraction, uses anhydrous sodium sulfate drying, promptly.
The preparation method of E, weight portion content 50% above Lignum Dalbergiae Odoriferae total flavones: Lignum Dalbergiae Odoriferae medical material alcohol extract, concentrate, add the water standardize solution, last macroporous adsorptive resins, washing, ethanol elution is collected alcohol eluen, and concentrate drying both got.
F, the said extracted thing is mixed, packing promptly.
The dosage form of this active component composition preparation can be tablet, capsule, oral liquid, injection, injectable powder, transdermal formulation, mucosa absorption preparation.
A kind of purposes that contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition is to be used to other various diseases of preventing and treating cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and being caused by cerebral ischemia.
Embodiment 2
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
50 parts of 50 parts of Radix Notoginseng total arasaponinss of Radix Salviae Miltiorrhizae total phenolic acids
20 parts of the total terpenes of 10 parts of Lignum Dalbergiae Odoriferae oils of Lignum Dalbergiae Odoriferae total flavones.
Preparation Method And The Use is consistent with embodiment 1.
Embodiment 3
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
99 parts of 20 parts of Radix Notoginseng total arasaponinss of 99 parts of TANSHINONES of Radix Salviae Miltiorrhizae total phenolic acids
20 parts of the total terpenes of Lignum Dalbergiae Odoriferae oil.
Preparation Method And The Use is consistent with embodiment 1.
Embodiment 4
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
99 parts of 20 parts of Radix Notoginseng total arasaponinss of 50 parts of TANSHINONES of Radix Salviae Miltiorrhizae total phenolic acids
20 parts of Lignum Dalbergiae Odoriferae total flavones.
Preparation Method And The Use is consistent with embodiment 1.
Embodiment 5
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
50 parts of 99 parts of Radix Notoginseng total arasaponinss of Radix Salviae Miltiorrhizae total phenolic acids.
Preparation Method And The Use is consistent with embodiment 1.
Embodiment 6
A kind of Radix Salviae Miltiorrhizae, Sanchi effective-component composition of containing, used medical material component weight proportion is:
99 parts of 10 parts of Radix Notoginseng total arasaponinss of Radix Salviae Miltiorrhizae total phenolic acids
10 parts of the total terpenes of Lignum Dalbergiae Odoriferae oil.
Preparation Method And The Use is consistent with embodiment 1.
Effect of the present invention is seen following experimental example:
Experimental example 1: the coronary heart disease active component composition causes the influence of Acute Myocardial Ischemia in Rats effect to pituitrin
Experiment grouping and dosage design, laboratory animal is divided into 6 groups at random:
1. animal pattern is organized: 10 of laboratory animals.Gavage 0.25%CMC (solvent control) every day, 1ml/100g body weight, continuous 5 days.
2. positive drug GUANXIN DANSHEN PIAN high dose group: 10 of laboratory animals.Gavage GUANXIN DANSHEN PIAN 80mg/100g body weight every day, continuous 5 days.
3. dosage group in the positive drug GUANXIN DANSHEN PIAN: 10 of laboratory animals.Gavage GUANXIN DANSHEN PIAN 40mg/100g body weight every day, continuous 5 days.
4. contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition high dose group: 10 of laboratory animals.Gavage every day and contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition 80mg/100g body weight, continuous 5 days.
5. contain dosage group in Radix Salviae Miltiorrhizae, the Sanchi effective-component composition: 10 of laboratory animals.Contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition 40mg/100g body weight every day, continuous 5 days.
6. contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition low dose group: 10 of laboratory animals.Contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition 20mg/100g body weight every day, continuous 5 days.
Experimental procedure, last administration be after 1 hour, the urethane with 25% (4ml/kg), and intraperitoneal anesthesia is faced upward the position and is fixed on the Mus platform, and II leads with the electrocardiograph mark.Voltage marking 1mv=10mm, chart speed 50mm/s.Record the preceding electrocardiogram of administration.Tail vein injection pituitrin (1U/kg) requires the interior injection of 5S to finish then.Electrocardiogram when immediate record 0S, 15S, 30S, 1min, 3min, 5min, 10min.(rat ST section was not obvious for the J point before and after pituitrin was given in measurement, the variation of ST section is represented in the variation that event is ordered with J) highly, the absolute value (Δ J) that displacement calculating changes, measure to give before the pituitrin simultaneously and give pituitrin after T wave height in 30 seconds, calculate changing value (Δ T), carry out the t check; The unusual rate of T ripple after 30 seconds after each group of record ARR number of animals takes place and gives pituitrin (towering, two-way, inversion, harmonic(-)mean be unusual) is carried out X2 and is checked.
Experimental result sees Table 1,2
Table 1 contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition to the influence of rat heart muscle ischemia due to the pituitrin (Δ T ripple changes,
N=10)
*P＜0.05,
*Compare with the blank group P＜0.01
Table 2 contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition to the influence of rat heart muscle ischemic injuries due to the pituitrin (routine number takes place in arrhythmia,
N=10)
*, * * compares p＜0.05, p＜0.01 with the blank group
Contain that Radix Salviae Miltiorrhizae, each dosage group of Sanchi effective-component composition change Acute Myocardial Ischemia in Rats J point due to the pituitrin and the T ripple changes remarkable antagonism is arranged, compared statistical significance (P＜0.05 or p＜0.01) with model control group, and the doses dependency has been arranged; Contain Radix Salviae Miltiorrhizae, each dosage group of Sanchi effective-component composition can antagonism pituitrin (pit) in various degree due to rat ventricular (mainly showing as atrioventricular block and ventricular premature contraction).Wherein contain Radix Salviae Miltiorrhizae, the incidence rate of dosage group is 30% in the Sanchi effective-component composition, compare p＜0.05 with the blank group, the incidence rate of coronary heart disease effective part group high dose group is 0%, compare p＜0.01 with model group, GUANXIN DANSHEN PIAN corresponding dosage group also can resist that rat electrocardiogram J point changes due to the pituitrin (pit), the T ripple changes and arrhythmia, compare with dosage, its effect is weaker than and contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition, but not statistically significant between group, these results all point out and contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition has the acute myocardial ischemia effect that the antagonism pituitrin causes, its effect is better than GUANXIN DANSHEN PIAN slightly.
Embodiment 2: contain the influence experiment grouping to anesthetized dog myocardial ischemia, myocardial infarction of Radix Salviae Miltiorrhizae, Sanchi effective-component composition, laboratory animal is divided into 6 groups at random:
1. animal pattern is organized: 6 of laboratory animals.
2. positive drug GUANXIN DANSHEN PIAN high dose group: 6 of laboratory animals.
3. dosage group in the positive drug GUANXIN DANSHEN PIAN: 6 of laboratory animals.
4. contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition high dose group: 6 of laboratory animals.
5. contain dosage group in Radix Salviae Miltiorrhizae, the Sanchi effective-component composition: 6 of laboratory animals
6. contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition low dose group: 6 of laboratory animals.
Experimental procedure, animal via pentobarbital sodium (30mg/kg) intravenous anesthesia, tracheal intubation connects SC-3 type electric pulmotor; Left side the 4th, 5 intercostals are opened breast, expose heart, cut off pericardium, make the pericardium bed; Separate 1/2 place under the anterior descending branch stage casing, coronary artery left side, threading is in order to ligation usefulness, and after the ligation, the following cardiac muscle of ligature occurs black purple at once, shows the ligation success, promptly causes the acute myocardial ischemia model; Make the fixed epicardial lead of multiple spot, trace epicardial electrogram.The ligation arteria coronaria is 15 minutes laggard line items before and after, as control value before the administration, duodenum is tested medicine or normal saline, 30 mapping point visceral pericardium electrographs of 15,30,60,120,180,240 minutes records after administration, raising greater than 2mv with the S-T section is criterion, (S-T section total mv that raises counts ∑-ST) and degree of myocardial ischemia (raise total points N-ST) of S-T section with this calculating myocardium degree of ischemia, and 60min, 120min, 180min, 240min get blood in the arteria coronaria hole after administration, and separation of serum is surveyed CK, LDH content respectively.After experiment finishes, take off heart immediately, normal saline flushing, weighing is heavy whole-heartedly, below the heart ligature, is parallel to coronary sulcus and is cut into 5 with the ventricle part is cross-section equably, then, places nitro tetrazole (N-BT) dye liquor, 37 ℃ of water-baths dyeing 15 minutes.The weigh weight of infarcted region (N-BT dye district) of every myocardium bilateral.Calculate the percentage ratio that infarct accounts for ventricle and accounts for cardiac weight.
Experimental result
1. contain the influence of Radix Salviae Miltiorrhizae, Sanchi effective-component composition to dog acute myocardial infarction scope (N-BT staining)
Contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition height, in two dosage groups can obviously dwindle myocardial infarct size.Show myocardial infarct size with the N-BT staining, the model control group infarct accounts for 34.2 ± 4.5% and 21.3 ± 3.3% of ventricle and cardiac weight respectively, contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition high dose group infarct accounts for 15.8 ± 3.4% and 9.8 ± 2.1% of ventricle and heart respectively, with model control group P＜0.01 relatively; Contain that dosage group infarct accounts for 23.9 ± 4.1% and 16.4 ± 1.9% of ventricle and heart respectively in Radix Salviae Miltiorrhizae, the Sanchi effective-component composition, with model control group P＜0.05 relatively; The middle and high dosage group of GUANXIN DANSHEN PIAN also can obviously be dwindled myocardial infarct size, compare P＜0.05 with model control group, compare with dosage, the GUANXIN DANSHEN PIAN effect is weaker than and contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition, but, the results are shown in Table 3 with comparing not statistically significant between the dosage group.
Table 3 contains the influence to coronary ligation dog myocardial infarction scope of Radix Salviae Miltiorrhizae, Sanchi effective-component composition
Compare with the blank group
*P＜0.05
*P＜0.01
* *P＜0.001
2. contain the influence of Radix Salviae Miltiorrhizae, Sanchi effective-component composition to acute myocardial infarction dog cardiac muscle sero-enzyme CPK, LDH
With model control group relatively, contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition height, middle dosage group and GUANXIN DANSHEN PIAN height, middle dosage group all can obviously show inhibition coronary ligation dog serum CPK and the active rising of LDH to sero-enzyme CPK, LDH; But with dosage contain Radix Salviae Miltiorrhizae, the Sanchi effective-component composition effect is better than GUANXIN DANSHEN PIAN, but with not statistically significant relatively between the dosage group.Table 4,5.
Table 4 coronary heart disease effective part group is to the influence (U/ml) of coronary ligation dog serum creatine phosphokinase (CK)
*P＜0.05,
*Compare with matched group p＜0.01
Table 5 contains the influence (U/l) to coronary ligation dog serum lactic acid dehydrogenase (LDH) of Radix Salviae Miltiorrhizae, Sanchi effective-component composition
*P＜0.05,
*Compare with matched group p＜0.01
3. contain the influence of Radix Salviae Miltiorrhizae, Sanchi effective-component composition to coronary ligation dog epicardial electrogram
Contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition, shows as the effect of having clear improvement of coronary artery ligation dog myocardial ischemia through duodenal administration: (∑-ST) and ST displacement surpass the lead variation of number (N-ST) of 2mv and compare with model control group that there were significant differences (P＜0.05 or 0.01 or 0.001) to contain epicardial electrogram ST field offset sum total after Radix Salviae Miltiorrhizae, Sanchi effective-component composition height, middle dosage group and GUANXIN DANSHEN PIAN height, the administration of middle dosage group; Compare with dosage, the GUANXIN DANSHEN PIAN effect is weaker than and contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition, but not statistically significant between group the results are shown in Table 6,7.
Table 6 contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition to the influence of experimental acute myocardial ischemia dog degree of myocardial ischemia (∑-ST)
Compare with the blank group
*P＜0.05
*P＜0.01
* *P＜0.001
Table 7 coronary heart disease effective part group is to the influence (N-ST) of experimental acute myocardial ischemia dog degree of myocardial ischemia
Compare * P＜0.05 * * P＜0.01 with the blank group
Embodiment 3 contains the influence to mice normal pressure resisting oxygen lack of Radix Salviae Miltiorrhizae, Sanchi effective-component composition
Experiment grouping and dosage design, laboratory animal is divided into 6 groups at random:
1. animal pattern is organized: 10 of laboratory animals.Gavage 0.25%CMC (solvent control) every day, 1ml/100g body weight, continuous 5 days.
2. positive drug GUANXIN DANSHEN PIAN high dose group: 10 of laboratory animals.Gavage GUANXIN DANSHEN PIAN 80mg/100g body weight every day, continuous 5 days.
3. dosage group in the positive drug GUANXIN DANSHEN PIAN: 10 of laboratory animals.Gavage GUANXIN DANSHEN PIAN 40mg/100g body weight every day, continuous 5 days.
4. contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition high dose group: 10 of laboratory animals.Gavage every day and contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition 80mg/100g body weight, continuous 5 days.
5. contain dosage group in Radix Salviae Miltiorrhizae, the Sanchi effective-component composition: 10 of laboratory animals.Contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition 40mg/100g body weight every day, continuous 5 days.
6. contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition low dose group: 10 of laboratory animals.Contain Radix Salviae Miltiorrhizae, Sanchi effective-component composition 20mg/100g body weight every day, continuous 5 days.
Experimental procedure moves into the bottom respectively with mice after 1 hour after the last administration and fills in the 150ml wide mouthed bottle of 15g sodica calx, seals.Observing its respiratory arrest is the dead used time, carries out the t check.
It is the same that other gets 6 groups of mices, and grouping and administration are the same, and after the last administration 1 hour, each treated animal tail vein injection respectively gave isoprenaline 2mg/kg, and put into wide mouthed bottle immediately and seal.Observational technique is the same.Experimental result is learned processing by statistics, does the t check and judges significance.
Experimental result shows, contains the time-to-live (P＜0.05 or 0.01) of Radix Salviae Miltiorrhizae, the equal energy of each dosage group of Sanchi effective-component composition significant prolongation normal pressure anoxia enduring animal; Contain Radix Salviae Miltiorrhizae, each dosage group dosage group of Sanchi effective-component composition simultaneously and also can obviously prolong and give the isoproterenol mice normal pressure anoxia enduring time-to-live (P＜0.05 or 0.01), prompting contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition has the effect that isoproterenol increases myocardial oxygen consumption of regulating; GUANXIN DANSHEN PIAN also has this effect, the results are shown in Table 8.
Table 8 contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition to the influence of mice time-to-live of normal pressure anoxia enduring
0.5%CMC is than * P＜0.05 * * P＜0.01;
With different third kidney of 0.5%CMC+ than #P＜0.05, ##P＜0.01
Claims (4)
1. one kind contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition, it is characterized in that: used medical material component weight proportion is:
Radix Salviae Miltiorrhizae total phenolic acids 10-99 part TANSHINONES 0-50 part
Radix Notoginseng total arasaponins 10-99 part Lignum Dalbergiae Odoriferae total flavones 0-50 part
The total terpene 0-20 of Lignum Dalbergiae Odoriferae oil part.
2. preparation method that contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition is characterized in that its preparation method may further comprise the steps:
A, weight portion content 50% above preparing salvianolic acids: red rooted salvia water extract is refining through macroporous adsorbent resin, and first water eluting discards water lotion, and the reuse ethanol elution is collected eluent, and concentrating under reduced pressure is drying to obtain;
The preparation method of B, weight portion content 50% above TANSHINONES: red rooted salvia water extract, concentrating under reduced pressure, aqueous precipitation, drying both got;
The preparation method of C, weight portion content 50% above Radix Notoginseng total arasaponins: macroporous adsorptive resins on the pseudo-ginseng water extract, first water eluting discards water lotion, and the reuse ethanol elution is collected eluent, reclaims ethanol, and concentrating under reduced pressure is drying to obtain;
The preparation method of D, the total terpene of weight portion content 50% above Lignum Dalbergiae Odoriferae oil volatility: the Lignum Dalbergiae Odoriferae medical material cuts off, and soaks, and vapor distillation is collected fraction, uses anhydrous sodium sulfate drying, promptly;
The preparation method of E, weight portion content 50% above Lignum Dalbergiae Odoriferae total flavones: Lignum Dalbergiae Odoriferae medical material alcohol extract, concentrate, add the water standardize solution, last macroporous adsorptive resins, washing, ethanol elution is collected alcohol eluen, and concentrate drying both got;
F, the said extracted thing is mixed, packing promptly.
3. Radix Salviae Miltiorrhizae, the Sanchi effective-component composition of containing according to claim 1 is characterized in that: the dosage form of this active component composition preparation can be tablet, capsule, oral liquid, injection, injectable powder, transdermal formulation, mucosa absorption preparation.
4. purposes that contains Radix Salviae Miltiorrhizae, Sanchi effective-component composition as claimed in claim 1 is characterized in that: be used to other various diseases of preventing and treating cardiovascular and cerebrovascular disease, senile dementia, cerebral infarction, cerebral ischemia and being caused by cerebral ischemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010256454 CN101912441A (en) | 2010-08-18 | 2010-08-18 | Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010256454 CN101912441A (en) | 2010-08-18 | 2010-08-18 | Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101912441A true CN101912441A (en) | 2010-12-15 |
Family
ID=43320188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010256454 Pending CN101912441A (en) | 2010-08-18 | 2010-08-18 | Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101912441A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109394832A (en) * | 2018-10-29 | 2019-03-01 | 华玉海 | A kind of compound dripping pill and preparation method thereof for treating cardiovascular and cerebrovascular diseases |
| CN109432168A (en) * | 2018-12-27 | 2019-03-08 | 山东万安药业股份有限公司 | The volatile oil and its preparation process of a kind of anti-Alzheimer disease and application |
| WO2019192599A1 (en) * | 2018-04-04 | 2019-10-10 | 天士力医药集团股份有限公司 | Pharmaceutical composition and application thereof |
| CN114732848A (en) * | 2022-04-29 | 2022-07-12 | 浙江维康药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating Alzheimer disease |
| RU2786387C2 (en) * | 2018-04-04 | 2022-12-20 | Тасли Фармасьютикал Груп Ко., Лтд. | Pharmaceutical composition and its use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919242A (en) * | 2005-08-24 | 2007-02-28 | 天津天士力现代中药研究开发有限公司 | Traditional Chinese medicine composition for treating cardiac and cerebral vascular disease |
| CN1919247A (en) * | 2005-08-24 | 2007-02-28 | 天津天士力现代中药研究开发有限公司 | Chinese medicine for treating cardiovascular and cerebrovascular disease |
| CN101073598A (en) * | 2006-05-17 | 2007-11-21 | 天津药物研究院 | Medicinal composition for treating cardiovascular and cerebrovascular disease and its preparation |
| CN101574391A (en) * | 2008-05-05 | 2009-11-11 | 天津天士力制药股份有限公司 | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside |
-
2010
- 2010-08-18 CN CN 201010256454 patent/CN101912441A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1919242A (en) * | 2005-08-24 | 2007-02-28 | 天津天士力现代中药研究开发有限公司 | Traditional Chinese medicine composition for treating cardiac and cerebral vascular disease |
| CN1919247A (en) * | 2005-08-24 | 2007-02-28 | 天津天士力现代中药研究开发有限公司 | Chinese medicine for treating cardiovascular and cerebrovascular disease |
| CN101073598A (en) * | 2006-05-17 | 2007-11-21 | 天津药物研究院 | Medicinal composition for treating cardiovascular and cerebrovascular disease and its preparation |
| CN101574391A (en) * | 2008-05-05 | 2009-11-11 | 天津天士力制药股份有限公司 | Prevention and treatment of diseases induced by microcirculation disturbance with compatible combination of total salvianolic acid and panax notoginoside |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019192599A1 (en) * | 2018-04-04 | 2019-10-10 | 天士力医药集团股份有限公司 | Pharmaceutical composition and application thereof |
| JP2021519335A (en) * | 2018-04-04 | 2021-08-10 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッドＴａｓｌｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｇｒｏｕｐ Ｃｏ．， Ｌｔｄ． | Pharmaceutical compositions and their uses |
| EP3777866A4 (en) * | 2018-04-04 | 2022-01-05 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition and application thereof |
| US11491173B2 (en) | 2018-04-04 | 2022-11-08 | Tasly Pharmaceutical Group Co., Ltd. | Pharmaceutical composition and application thereof |
| RU2786387C2 (en) * | 2018-04-04 | 2022-12-20 | Тасли Фармасьютикал Груп Ко., Лтд. | Pharmaceutical composition and its use |
| JP7345493B2 (en) | 2018-04-04 | 2023-09-15 | タスリー・ファーマシューティカル・グループ・カンパニー・リミテッド | Pharmaceutical compositions and their uses |
| CN109394832A (en) * | 2018-10-29 | 2019-03-01 | 华玉海 | A kind of compound dripping pill and preparation method thereof for treating cardiovascular and cerebrovascular diseases |
| CN109432168A (en) * | 2018-12-27 | 2019-03-08 | 山东万安药业股份有限公司 | The volatile oil and its preparation process of a kind of anti-Alzheimer disease and application |
| CN114732848A (en) * | 2022-04-29 | 2022-07-12 | 浙江维康药业股份有限公司 | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating Alzheimer disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101912441A (en) | Effective part composite containing salvia miltiorrhiza bunge and panax pseudoginseng and preparation method and application thereof | |
| NO335203B1 (en) | Treatment of aspirin resistance with radix sage miltiorrhiaze, its extract and composition. | |
| CN101129469B (en) | Traditional Chinese medicine composition for preventing and controlling cardiovascular disease | |
| CN101234137B (en) | Drug for curing coronary disease | |
| CN100435811C (en) | Apoplexy treating medicine composition | |
| CN103655673A (en) | Compound gingko dropping pill and preparation method thereof | |
| JPS626687B2 (en) | ||
| CN1321651C (en) | Oral cavity spray containing two effective parts of compound red sage root formula and its preparation process | |
| CN1970050B (en) | Pharmaceutical composition for treating arrhythmia and preparation process thereof | |
| CN1088998C (en) | Intravenous injection medicine for curing ischemic cerebrovascular disease and its preparing method | |
| ZA200601412B (en) | Treatment of aspirin resistance with radix salviae miltiorrhizae, its extract and composition | |
| CN102008571B (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN104740054A (en) | Pharmaceutical composition for treating myocardial ischemia as well as preparation method and use of pharmaceutical composition | |
| CN101700264B (en) | Application of pseudo-ginseng and extract thereof in preparing medicament for curing and/or preventing diabetic neuropathies | |
| CN112294874A (en) | Preparation method of pharmaceutical composition and application of pharmaceutical composition in treating diplocardia | |
| CN101468053A (en) | Pharmaceutical composition containing notoginseng and ginseng as well as preparation and application thereof | |
| CN101084965A (en) | Safflower compound preparation and its preparation technology | |
| CN104547027B (en) | Preparation method and application of salvia miltiorrhiza leave and panax notoginseng leaf extract | |
| CN116327825B (en) | A Chinese medicinal composition for treating cardiovascular diseases, and its preparation method | |
| CN100556419C (en) | A kind of dispersible tablet that contains Radix Salviae Miltiorrhizae and Sanchi effective-component and preparation method thereof | |
| CN103193848B (en) | Pseudoginsenoside RT6 and extraction method thereof, and applications of pseudoginsenoside RT6 drug | |
| CN1251717C (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina pectoris | |
| CN101229230A (en) | Chinese traditional medicine mixture for curing senile dementia | |
| CN1689593A (en) | Method for preparing ginseng and aconite powdered injection | |
| CN1935198A (en) | Chinese medicine compound preparation and its preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20101215 |